Antiobesity potential of Piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats
Abstract
Background
Black pepper or Piper nigrum is a well-known spice, rich in a variety of bioactive compounds, and widely used in many cuisines across the world. In the Indian traditional systems of medicine, it is used to treat gastric and respiratory ailments. The purpose of this investigation is to study the antihyperlipidemic and antiobesity effects of piperonal in high-fat diet (HFD)-induced obese rats.
Methods
Piperonal, an active constituent of Piper nigrum seeds, was isolated and confirmed by HPLC, 1H and 13C NMR spectroscopy. Male SD rats were fed on HFD for 22 weeks; Piperonal was supplemented from the 16th week as mentioned in the experimental design. Changes in body weight and body composition were measured by TOBEC, bone mineral composition and density were measured by DXA, and adipose tissue distribution was measured by 7 T–MRI. Plasma levels of glucose, insulin, insulin resistance and lipid profiles of plasma, liver and kidney, adipocyte hormones and liver antioxidants were evaluated using standard kit methods. Expression levels of adipogenic and lipogenic genes, such as PPAR-γ, FAS, Fab-4, UCP-2, SREBP-1c, ACC, HMG-COA and TNF-α were measured by RT-PCR. Histopathological examination of adipose and liver tissues was also carried out in experimental rats.
Results
HFD substantially induced body weight, fat%, adipocyte size, circulatory and tissue lipid profiles. It elevated the plasma levels of insulin, insulin resistance and leptin but decreased the levels of adiponectin, BMC and BMD. Increased expression of PPAR-γ, FAS, Fab-4, UCP-2, SREBP-1c, ACC, and TNF-α was noticed in HFD-fed rats. However, supplementation of piperonal (20, 30 and 40 mg/kg b.wt) for 42 days considerably and dose-dependently attenuated the HFD-induced alterations, with the maximum therapeutic activity being noticed at 40 mg/kg b.wt.
Conclusions
Piperonal significantly attenuated HFD-induced body weight and biochemical changes through modulation of key lipid metabolizing and obesogenic genes. Our findings demonstrate the efficacy of piperonal as a potent antiobesity agent, provide scientific evidence for its traditional use and suggest the possible mechanism of action.
Keywords
Obesity PPARγ Insulin resistance Piper nigrum PiperonalAbbreviations
- ACC
Acetyl-CoA carboxylase
- BMC
Bone mineral concentration
- BMD
Bone mineral density
- DXA
Dual X ray absorptiometry
- Fab-4
Fatty acid binding protein-4
- Fas
Fatty acid synthase
- HDL
High density lipoproteins
- HFD
High fat diet
- HMG-CoA reductase
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
- HPLC
High-performance liquid chromatography
- LDL
Low density lipoproteins
- NMR
Nuclear magnetic resonance spectroscopy
- PPAR-ϒ
Peroxisome proliferator-activated receptor gamma
- SD rats
Sprague Dawley rats
- SREBP-1c
Sterol regulatory element-binding transcription factor 1c
- TC
Total cholesterol
- TG
Total triglycerides
- TNF-α
Tumor necrosis factor-α
- TOBEC
Total body electrical conductivity
- UCP
Uncoupling protein-2
- VLDL
Very low density lipoproteins
Background
The incidence of overweight and obesity is mounting worldwide in recent years and since they are predisposed to hypertension, type 2 diabetes, hyperlipidemia, nonalcoholic fatty liver and cardiovascular diseases, they gravely threaten public health [1, 2, 3, 4]. The World Health Organization report-2014 mentions that 1.9 billion adults are overweight in the world, of which 600 million are obese. The obesity epidemic is no longer limited to western cultures, but is becoming rampant worldwide with such countries as People’s Republic of China, India, Brazil and Mexico being most widely affected [5]. Unless effective measures are taken, the prevalence of obesity of 10–15% among adults will double over the next two decades; childhood obesity is even more alarming [6, 7]. These distressing facts draw attention and necessitate intensive efforts to lower the prevalence of overweight-obesity and the burden of its clinical and monetary repercussions.
Although proper dietary pattern, exercise habits, behavioral modification and pharmacotherapy are widely recommended to prevent obesity and lifestyle-related diseases, their prevalence seems to be only increasing [8]. Many attempts have been made to correct the metabolic disparity of obesity condition, including a number of drugs like fibrates, sibutramine and Orlistat, but they have significant side effects like nausea, headache, vomiting etc. Hence, alternative therapies derived from natural products have gained attention. Certain dietary components/ herbal formulations have been in use to suppress obesity and associated ailments but many of them have not undergone adequate systematic, scientific and clinical studies [9, 10, 11, 12].
Adipogenesis and fatty-acid metabolism are organized by PPAR and SREBP family members through transcriptional regulation of target genes [13, 14, 15]. PPAR-γ is majorly expressed in adipose tissue, PPAR-α is expressed in liver and PPAR-δ is ubiquitously expressed [16, 17]. Moreover, it is extensively implicit that the regulation of lipid metabolism and energy homeostasis is achieved through HMG-CoA reductase (HMGR), acetyl-CoA carboxylase (ACC), fatty-acid synthase (FAS), fatty-acid-binding protein-4 (Fab-4), TNF-α (Tumor necrosis factor), thermoregulatory proteins and uncoupling proteins [18]. TNF-α, one of the key mediators of the inflammatory response in obesity, is articulated by a number of mechanisms, namely, infiltrating macrophages, adipocytes in the hypertrophic adipose tissue, microglia and also neurons in the hypothalamus. One or more of the above-mentioned enzymes/proteins of lipid metabolism can be considered as potential targets to develop novel therapeutics to treat obesity. In the present study, we aimed to isolate and evaluate the antiobesity activities of piperonal, an active constituent of Piper nigrum seeds on high-fat diet-induced obesity.
Piper nigrum belongs to the tropical plant family Piperaceae, which is a rich source of diverse biologically active phytochemicals [19] and food-grade spices. Piperine, one of the major pungent constituents of Piper nigrum, has been found to possess interesting pharmacological effects. Increasing evidence from in vitro and in vivo studies has shown that it possesses anticancer [20, 21] and neuroendocrine modulator effects [22]. A few studies have demonstrated its expectorant, antiflatulent and cholesterol-lowering properties [23, 24]. However, its antiobesity activity remains largely unexplored. Furthermore, its protective effect on obesity-induced inflammation is unclear [25]. Therefore, the present study was aimed to isolate piperonal and evaluate its antiobesity activities in HFD-induced obese rats.
Methods
Chemicals
For analyzing plasma glucose and insulin, commercially available kits were procured from Stanbio Laboratory, USA and Bio-Merieux, RCS, Lyon, France, respectively. Plasma was used for analyzing total cholesterol, triglycerides, phospholipids, free fatty acids, VLDL and HDL by colorimetric methods using kits (Nicholas Piramal India Ltd., Mumbai). Orlistat (Cat No 04139) was obtained from Sigma-Aldrich. All other reagents used in the experiments were of analytical grade and of high purity. Trireagent and cDNA preparation kits were obtained from Qiagen.
Animals and treatments
Male SD rats weighing 180–200 g were randomly divided into six groups of six each. Normal control rats were fed with normal pellet diet as per AIN-93 guidelines, while the other groups of animals were fed with HFD for 22 weeks. The composition of HFD is as previously described by us [26]. Piperonal was supplemented to selected HFD groups for 6 weeks from 16th week, as mentioned in the experimental design below. Experiments were performed at the National Center for Laboratory Animal Sciences, National Institute of Nutrition, Hyderabad, India (Regd. No. 154/RO/C/1999a/CPCSEA). Animals were placed in cages at 22 ± 2 °C, with 14–16 air changes per hour with a relative humidity of 50–60% and 12 h light/dark cycle. All procedures involving laboratory animals were in accordance with the Institute Animal Ethical Committee (IAEC No: 36 a/2012(i)/a/−CPCSEA/−IAEC/SVU/MB; Dt.01.07.2012).
Isolation and characterization of piperonal
Piperonal was isolated at the Natural Products Division, Indian Institute of Chemical Technology, Hyderabad, India, from ethylacetate extract of black pepper seeds and purity was checked by HPLC equipped with Phenomenex Luna C18 column (150–4.6 mm, 5 m i.d.). Acetonitrile-water system was selected as mobile phase, PDA detector was used to measure the wavelength and peak position and structure was confirmed by 1H NMR and 13C NMR. The procedures used are in line with Rao et al. [27].
Drug dosage
Piperonal weighing 1.6, 1.8 and 2.4 g, each mixed with 4 kg of HFD, was prepared to get a dose of 20, 30 and 40 mg/kg b.wt. Twenty grams of diet/day/rat were given to the groups as shown in the experimental design. The exact dose of piperonal consumed was calculated from daily food intake.
Experimental design
- Group 1:
Normal diet control
- Group 2:
High-fat diet control (HFD control)
- Group 3:
: HFD + Orlistat (5 mg/kg b.wt)
- Group 4:
HFD + piperonal (20 mg/kg b.wt)
- Group 5:
HFD + piperonal (30 mg/kg b.wt)
- Group 6:
HFD + piperonal (40 mg/kg b.wt)
Body weight and feed efficiency ratio
The body weight of the experimental rats was assessed once a week, while the food consumed and leftover was measured daily. For the measurement of nutrient metabolites like food intake, water intake, urine volume and fecal weight, both control and experimental rats were placed in the metabolic cages for 72 h (Techniplast, Italy).
Body composition by Total body electrical conductivity (TOBEC)
At the end of the experiment, body composition which includes lean mass, fat-free mass, fat%, total fat (g), total body Na, K levels and water content was measured in all experimental groups by Total Body Electrical Conductivity (TOBEC) using small-animal body composition analysis system (EM-SCAN, Model SA-3000 Multi detector, Springfield, USA) as described by us previously [26]. The following body composition parameters were obtained mathematically, where E stands for total electrical conductivity. i) Total body fat: total body weight – lean body mass; ii) Fat percentage: (total body fat × 100)/total body weight; iii) Lean mass: 0.5 × E + 0.3 × total body weight; iv) Fat-free mass: 16.28 + 0.4 x E; v) Total body sodium (TB Na) (mg): (2.5 × E) + 49.1; vi) Total body potassium (TB K) (mg): (4.95 × E) + 164.4; vii) Total body water (TBW): 31.5 + 1.8 × E.
The above prediction equations have been reported to be very accurate for Wistar, Sprague Dawley, F-344 N, CFY, WKY and Holtzman rats [28].
Estimation of BMC and BMD by DXA
The body composition of the experimental animals was assessed at the end of the experiment by Dual-X ray absorptiometry (DXA) using body composition analysis system (Halogen 1000 series). DXA data were used to compare the levels of body adiposity, bone mineral concentration (BMC) and bone mineral density (BMD) between the control and experimental groups, and calculations were made according to manufacturer’s protocols [29].
Plasma lipid profile
At the end of the experiment, blood was collected from overnight-fasted rats by retro-orbital puncture method. Plasma was separated by centrifugation at 2500 rpm for 15 min and stored at 80 °C for further biochemical analysis. Total cholesterol (TC), HDL, VLDL, LDL and triglyceride levels (TGs) were estimated by CHOD-PAP method, GPO-PAP method; phospholipids (PLs) and free fatty acids (FFAs) were assessed as described by us previously [12].
Blood glucose, insulin and insulin resistance
Plasma glucose was estimated using kits (Cat No 1060–500, Stanbio Laboratory, USA). Plasma level of insulin was determined using kits from Bio-Merieux, RCS, Lyon, France. Insulin resistance was calculated using the homeostasis model assessment.
Oral glucose tolerance test (OGTT)
Oral glucose tolerance test was performed at the end of the experiment; after overnight fasting, glucose was administered orogastrically at a dose of 2 g/kg body weight and blood samples were collected from supraorbital sinus at intervals of 0, 30, 60, 90 and 120 min and glucose level was estimated [26].
Estimation of leptin, adiponectin, lipase and α-amylase
Plasma leptin and adiponectin levels were measured by using enzyme-linked immunosorbent assay kits (Crystal Chem, Downers Grove, IL, USA), performed in duplicate, as per the manufacturer’s guidelines and expressed in ng mL−1. Alpha-amylase and lipase activities were determined by kinetic method using the commercial kits of Labtest, Minas Gerais, Brazil and Bioclin, Minas Gerais, Brazil, respectively [26].
Estimation of tissue lipids
Tissue (Liver, kidney) lipids were extracted from the experimental animals as per Floch et al. [30] using a chloroform–methanol mixture (2:1, v/v). The tissues were rinsed with ice-cold physiological saline, dried, homogenized in cold chloroform-methanol (2:1, v/v) and the contents were extracted after 24 h. The extraction was repeated four times. The combined filtrate was washed with 0.7% KCl and the aqueous layer was discarded. The organic layer was made up to a known volume with chloroform and used for tissue lipid analysis.
Adiposity index
Adiposity index (AI), a measure of the total weight of the visceral fat depots (epididymal, retroperitoneal and mesenteric) in the body, was determined according to Taylor and Phillips method [31] using the formula: AI = (sum of the weights of the visceral fat depots/body weight) × 100.
Organ weights
At the end of the experiment, rats were fasted overnight and euthanized by CO2 inhalation and subjected to necropsy. Major vital organs like heart, lungs, liver, kidneys, mesenteric fat pads, epididymal and retroperitoneal fat pads were collected. After detailed necropsy examination, these organs were weighed and organ-to-body weight ratio was measured.
Liver antioxidants analysis
After the completion of the experimental period, rats were anesthetized, sacrificed; the liver was excised, rinsed in ice-cold normal saline followed by ice-cold 10% KCl solution, blotted, dried and weighed. A 10% w/v homogenate was prepared in ice-cold KCl solution and centrifuged at 2000 rpm for 10 min at 4 °C. The supernatant thus obtained was used for the estimation of thiobarbituric acid substances (TBARS) [32], assay of catalase [33] (CAT), reduced glutathione (GSH) [34], superoxide dismutase (SOD) [35] and glutathione peroxidase (GpX) [36].
RT- PCR analysis
Total RNA was isolated from adipose tissue by using tri-reagent (Sigma-Aldrich, USA) according to manufacturer’s protocol and reverse-transcribed to obtain cDNA using DNA synthesis kit (Applied Biosystems, Foster City, USA).
Primer sequences of genes used in RT-PCR
| Gene | Gene Bank No | Sense | Antisense |
|---|---|---|---|
| PPAR-γ | NM_013124 | CTGACCCAATGGTTGCTGATTAC | GGACGCAGGCTCTACTTTGATC |
| TNF-α | NM_012675 | GTCGTAGCAAACCACCAAG | AGAGAACCTGGGAGTAGATAAG |
| FAS | NM_017332 | GAGGACTTGGGTGCCGATTAC | GCTGTGGATGATGTTGATGATAGAC |
| Fab-4 | NM_053365 | TCACCCCAGATGACAGGAAA | CATGACACATTCCACCACCA |
| SREBP-1c | NM_012767 | CGCTACCGTTCCTCTATCA | TCGCAGGGTCAGGTTCT |
| UCP-2 | NM_019354 | TAAAGCAGTTCTACACCAAGGG | CGAAGGCAGAAGTGAAGTGG |
| HMG-CoA R | NM_013134 | GGGACCAACCTTCTACCTCAG | GACAACTCACCAGCCATCAC |
| ACC | NM_022193 | CCTTCTTCTACTGGCGACTGAG | TAAGCCTTCACTGTGCCTTCC |
| β- actin | NM_031144 | GGCACCACACTTTCTACAAT | AGGTCTCAAACATGATCTGG |
Histopathology of adipose and liver tissues
Liver and adipose tissues were collected from experimental rats, cut into pieces and kept in 10% formalin solution. A small piece of the tissue was sectioned with microtome, fixed on slides, stained using haematoxylin and eosin (H&E) staining procedures and observed under an optical microscope with 40X magnification and photographed.
MRI analysis
Body fat distribution was determined by 7 Tesla MRI. The rats were placed in the magnet and fixed in a nonmagnetic device. For the detection of pure fat images, respiration-triggered water- suppressed Spin Echo sequences (repetition time: 744 ms, echo time: 12.24 ms, four averages, field view: 70 mm, matrix: 192–192, water suppression: Gauss pulse 3.9 ms, 701 HZ bandwidth) were used to obtain 30 slices (slice thickness: 2 mm) in the abdominal region. For the data analysis, 20 slices at a reproducible position covering the area from the nose to anus were considered. The area of retraperitoneal fat was visually identified in the selected slice package. Tissue volumes were calculated by multiplying the corresponding number of segmented pixels by in-plane pixel dimensions and the slice thickness.
Statistical analysis
Results are expressed as the Mean ± S.D. All the grouped data were statistically evaluated with SPSS\19.0 software. Hypothesis testing methods included one-way analysis of variance (ANOVA) followed by Least Significant Difference (LSD) test. Significance level at p < 0.05, 0.01, and 0.001 was considered for various parameters to indicate statistical significance.
Results
HPLC and NMR analysis of piperonal
HPLC analysis of Piperonal. Pipernoal retention time 21.2 min
NMR analysis of isolated piperonal; (a) 1H NMR analysis; (b) 13C NMR analysis
Estimation of body composition, BMC and BMD
Effect of piperonal on Body weight parameters, BMC and BMD in normal and experimental obese rats
| Groups | Body weight (g) | Lean body mass (g) | Total fat (g) | Fat free mass (g) | Fat % | TB H2O (mg) | TB Na (mg) | TB P (mg) | BMC (g) | BMD (g/sq./cm) |
|---|---|---|---|---|---|---|---|---|---|---|
| ND control | 301.5±11.0 | 285.3±8.8 | 16.3±2.7 | 130.4±3.5 | 5.3±0.7 | 616.5±16.7 | 1023.7±28.0 | 2094.1±55.0 | 8.2 ± 0.69 | 0.16 ± 0.001 |
| HFD control | 506.0±9.3a* | 391.3±9.8 a* | 114.5±7.1a* | 172.8±3.9 a* | 22.6±1.3 a* | 750.5±24.1 a* | 1247.2±40.1 a* | 2536.5±79.4 a* | 5.5 ± 0.29 a* | 0.11 ± 0.002 a* |
| HFD + Orlistat 5 mg/kg b.wt | 450.1±22.8b* | 385.3±23.8 b* | 64.88±7.4b* | 170.3±9.5 b* | 14.3±1.7 b* | 782.5±52.3 b* | 1300.3±87.2 b* | 2650.3±166.8 b* | 7.1 ± 0.32 b* | 0.12 ± 0.001 |
| HFD + Piperonal 20 mg/kg b.wt | 490.3±18.0NS | 396.8±9.4 | 93.5±10.2 | 175.0±3.7 | 18.9±1.4 | 781.1±14.9 | 1298.1±24.8 | 2636.6±49.4 | 6.2 ± 0.02 | 0.13 ± 0.003 |
| HFD + Piperonal 30 mg/kg b.wt | 456.0±15.7 b* | 376.9±12.6 | 79.0±6.6 | 167.1±5.1 | 17.2±1.2 | 752.3±25.7 | 1250.1±43.1 | 2542.1±84.5 | 6.6 ± 0.03 | 0.17 ± 0.002 |
| HFD + Piperonal 40 mg/kg b.wt | 454.6±12.3 b* | 391.8±8.5 b* | 62.8±8.1b* | 173.0±3.3 b* | 13.7±1.5 b* | 798.1±18.7 b* | 1326.3±31.1 b* | 2693.0±62.0 b* | 7.7 ± 0.01 b* | 0.14 ± 0.001 b* |
Estimation of blood glucose, insulin and insulin resistance
Effect of Piperonal on plasma glucose, insulin and insulin resistance in normal and experimental obese rats
| Groups | Glucose (mg dl−1) | Insulin (μU ml−1) | Insulin resistance |
|---|---|---|---|
| ND control | 90.9±7.1 | 6.0±0.2 | 3.6±.0.4 |
| HFD Control | 150.1±9.7a* | 27.2±0.4 a* | 6.3±0.2a* |
| HFD + Orlistat 5 mg/kg b.wt | 103.1±4.9 b* | 15.8±1.4 b* | 4.5±0.6 b* |
| HFD + Piperonal 20 mg/kg b.wt | 140.7±7.2 | 24.3.7±0.44 | 6.0±0.2 |
| HFD + Piperonal 30 mg/kg b.wt | 131.7±2.3 b* | 19.7.4±0.5 b* | 5.1±0.2 b* |
| HFD + Piperonal 40 mg/kg b.wt | 101.5±5.5 b* | 17.9±0.24 b* | 4.8±0.3 b* |
Oral glucose tolerance test (OGTT)
Effect of Piperonal on glucose tolerance in normal control and experimental obese rats. Values are mean ± SD, n = 6; Values are statistically significant at *p < 0.05; a* Significantly different from normal control; b* Significantly different from HFD control
Estimation of leptin, adiponectin and activities of lipase and amylase
Effect of Piperonal on leptin, adiponectin, amylase and pancreatic lipase in normal control and experimental obese rats. Values are mean ± SD, n = 6; Values are statistically significant at *p < 0.05; a* Significantly different from normal control; b* Significantly different from HFD control
Estimation of plasma lipid profiles
Effect of Piperonal on Plasma lipid profiles in normal and experimental obese rats
| Groups | TC (mg/dl) | TG (mg/dl) | HDL (mg/dl) | LDL (mg/dl) | VLDL (mg/dl) | Phospholipids (mg/dl) | Free fatty acids (mg/dl) |
|---|---|---|---|---|---|---|---|
| ND control | 113.5±11.4 | 130.6±6.6 | 50.0±3.1 | 50.8±4.6 | 35.7±2.2 | 85.7±5.3 | 64.6±5.1 |
| HFD control | 311.1±20.2 a* | 259.5±8.5 a* | 26.6±2.9 a* | 130.8±5.9 a* | 81.7±4.1 a* | 147.9±5.7 a* | 116.1±4.6 a* |
| HFD + Orlistat5mg/kg b.wt | 142.6±9.8 b* | 136.6±11.1 b* | 46.8±3.4 b* | 55.8±5.5 b* | 41.6±4.4 b* | 100.3±5.2 b* | 71.2±4.3 b* |
| HFD+ Piperonal 20 mg/kg b.wt | 254.0±9.8 | 214.0±9.4 | 31.3±2.4 | 118.8±9.6 | 84.7±3.7 | 135.3±4.3 | 106.4±5.2 |
| HFD+ Piperonal 30 mg/kg b.wt | 211.0±8.2 | 188.5±10.4 | 38.7±2.1 | 94.7±5.8 | 74.1±4.6 | 113.2±10.6 | 88.6±7.6 |
| HFD+ Piperonal 40 mg/kg b.wt | 158.3±9.8 b* | 145.8±10.1 b* | 46.4±5.1 b* | 53.1±5.3 b* | 46.7±4.7 b* | 97.9±5.3 b* | 68.1±5.1 b* |
Estimation of tissue lipids
Effect of Piperonal on Tissue lipid profiles (Liver, Kidney) in normal and experimental obese rats
| Groups | TC (mg/g tissue) | TG (mg/g tissue) | Phospholipids (mg/g tissue) | Free fatty acids (mg/g tissue) | ||||
|---|---|---|---|---|---|---|---|---|
| Liver | Kidney | Liver | Kidney | Liver | Kidney | Liver | Kidney | |
| ND control | 71.8±5.1 | 51.9±6.4 | 105.7±10.5 | 79.7±7.5 | 125.2±8.6 | 71.5±7.2 | 84.3±5.1 | 49.4±6.8 |
| HFD control | 143.8±16.4 a* | 132.1±7.9 a* | 218.3±11.1 a* | 145.7±8.1a* | 203.4±12.7a* | 150.9±9.6a* | 180.9±6.7a* | 119.3±9.4a* |
| HFD + Orlistat5mg/kg b.wt | 76.8±6.5b* | 73.5±5.1b* | 119.5±13.1b* | 87.6±7.4b* | 134.8±8.7b* | 80.2±6.6b* | 87.8±5.1b* | 61.2±3.5b* |
| HFD + Piperonal 20 mg/kg b.wt | 129.8±10.6 | 129.6±6.2 | 200.1±15.3 | 136.4±4.5 | 200.3±15.1 | 137.9±9.3 | 148.9±7.1 | 105.1±5.4 |
| HFD + Piperonal 30 mg/kg b.wt | 118.2±16.9 | 109.6±6.2 | 182.6±7.4 | 123.9±7.3 | 175.1±8.8 | 123.7±4.3 | 135.5±11.1 | 84.9±5.1 |
| HFD + Piperonal 40 mg/kg b.wt | 94.6±10.1b* | 85.6±5.6b* | 142.1±8.1b* | 103.1±3.9b* | 121.1±10.4b* | 88.1±8.3b* | 94.8±4.1b* | 67.9±5.8b* |
Organ weights and adiposity index
Effect of Piperonal on Organ weights in normal and experimental obese rats
| Groups | Liver (g) | Heart (g) | Kidney (g) | Testis(g) | Retroperitoneal (g/100 g b.wt fat) | Mesentric (g/100 g b.wt fat) | Epididymal (g/100 g b.wt fat) |
|---|---|---|---|---|---|---|---|
| ND control | 8.3±0.4 | 0.9±0.2 | 2.1±0.2 | 2.3±0.1 | 0.8±0.1 | 0.7±0.1 | 1.0±0.2 |
| HFD control | 14.0±0.2a* | 1.6±0.2a* | 3.9±0.11a* | 1.8±0.1a* | 3.5±0.4 a* | 2.1±0.2a* | 2.8±0.5 a* |
| HFD + Orlistat 5 mg/kg b.wt | 10.4±0.6b* | 1.0±0.1b* | 2.4±0.3b* | 2 ±0.1 | 1.1±0.1b* | 1.2±0.2b* | 1.2±0.2b* |
| HFD + Piperonal 20 mg/kg b.wt | 13.3±0.5 | 1.3±0.1 | 3.7±0.3 | 1.8±0.3 | 2.9±0.1 | 1.9±0.2 | 2.3±0.3 |
| HFD + Piperonal 30 mg/kg b.wt | 11.6±0.4b* | 1.0±0.2 | 3.5±0.1 | 1.9±0.2 | 2.4±0.2 | 1.5±0.1 | 1.9±0.2 |
| HFD + Piperonal 40 mg/kg b.wt | 10.0±0.6 b* | 0.9±0.1b* | 2.7±0.2b* | 2.1±0.01 | 1.3±0.2b* | 0.9±0.1b* | 1.1±0.1b* |
Effect of Piperonal on fat pad weights in normal control and experimental obese rats. Values mean ± S.D., n = 6. Values are statistically significant at *p < 0.05; a* Significantly different from normal control; b* Significantly different from HFD control
Liver antioxidants
Effect of Piperonal on liver antioxidants in normal and experimental obese rats. Values mean ± S.D., n = 6. Values are statistically significant at *p < 0.05; a* Significantly different from normal control; b* Significantly different from HFD control
Effect of Piperonal on expression of adipogenic and lipid marker genes
Effect of Piperonal treatment on tissue mRNA levels of adipogenic and lipogenic genes (PPARγ, TNFα, FAS, Fab-4, SREBP-1c, ACC, HMG-CoA R and UCP-2): L1- Normal control group; L2 - HFD control group; L3- HFD + Orlistat 5 mg/kg b.wt; L4- HFD + Piperonal 20 mg/kg b.wt; L5 - HFD+ Piperonal 30 mg/kg b.wt; L6 - HFD + Piperonal 40 mg/kg b.wt. Gr-1: Normal Control; Gr-2: High Fat Diet (HFD) Control; Gr-3: HFD+Orlistat 5mg/kg b.wt; Gr-5: HFD+Piperonal 30mg/kg b.wt; Gr-6: HFD+Piperonal 40mg/kg b.wt. Values are mean ± SD, n=6; Values are statistically significant at *p > 0.05; a*Significantly different from Normal control b*Significantly different from HFD control
Effect of piperonal on liver histology of normal control and experimental obese rats. a Normal control group showing normal histopathology of the liver; (b) HFD control group shows increased interstitial space and distorted intercalated disc; (c) HFD + Orlistat 5 mg/kg b.wt; (d) HFD + Piperonal 20 mg/kg b.wt, (e) HFD + Piperonal 30 mg/kg b.wt, and (f) HFD + Piperonal 40 mg/kg b.wt administration showed decreased interstitial space and less distorted intercalated disc. HC: Hepatocytes, FD; Fat Droplets
Effect of piperonal on adipose tissue histology of control and experimental obese rats. Normal control; (a) Adipose tissue histological observation clearly showed normal cell size. (b) HFD control rats showed enlarged adipocytes; Supplementation of orlistat and piperonal at different doses 20, 30, 40 mg/kg b.wt decreased fat cell size and volume (Fig. 9 c, d, e, f). AC: Adipocyte Cell; AV: Adipocyte Volume
Effect of piperonal on adipose tissue distribution in control and experimental obese rats. Extensive distribution of fat in HFD fed rats is seen in (b) (HFD control), Supplementation of orlistat (5 mg/kg b.wt) and piperonal at different doses 20, 30, 40 mg/kg b.wt decreased fat content and distribution (c, d, e, f). A). Normal Control, B). High Fat Diet (HFD) Control, C). HFD+Orlistat 5mg/kg b.wt, D). HFD+Piperonal 20mg/kg b. wt, E). HFD+Piperonal 30mg/kg b. wt, F) HFD+Piperonal 40mg/kg b. wt
Histopathological observations
In histological examination, the liver of HFD-fed rats showed signs of hepatic steatosis with severe swelling of hepatocytes and fat accumulation (Fig-8a and b). Interestingly, the liver sections made from piperonal (40 mg/kg b.wt)-treated rats did not show intense changes as that of HFD-fed control rats indicating its protective effect on them, though insufficient. On the same lines, the histology sections of adipose tissue of HFD-fed rats showed hypertrophy and hyperplasia of adipocytes when compared with normal control group (Fig. 9b). Supplementation of piperonal decreased fat cell size and volume in a dose-dependent manner, with the maximum therapeutic effect being observed at 40 mg/kg b.wt, as can be seen in Fig. 9c–f, indicating the antiadipogenic activity of piperonal.
Adiposity distribution by 7 tesla magnetic resonance imaging
7 T–MRI was used to measure the magnitude of adipose tissue formed, its distribution and its effect on other organ volumes (brain and kidney). Extensive distribution of fat in HFD-fed rats is seen (Fig. 10b, HFD control); however, supplementation of piperonal decreased retroperitoneal fat content, its distribution and increased brain volume in a dose-dependent manner, with the maximum therapeutic effect being observed at 40 mg/kg b.wt (Fig. 10c–f).
Discussion
A number of advances in our understanding of the physiological and molecular basis of appetite and body weight regulation have come from animal models. Diet-induced obesity (DIO) in animals shares many features with human obesity and hence they, more particularly rodent models, are extensively used to find efficient functional foods or their active ingredients for preventing and/or reducing obesity and associated co-morbidities [23, 37, 38, 39]. In the present study, HFD-fed group displayed significantly higher body weight gain compared to normal diet-fed group, which is the hallmark of obesity [37]. There is a good rapport between body weight and its composition in relation to organ weights and the menace of metabolic disorders [40]. In the present study, the inclusion of piperonal in diet showed a more significant reduction in body weight when compared with HFD-fed control rats. Interestingly, piperonal had no apparent suppressive effect on feeding patterns of HFD-fed rats, which indicates that piperonal-induced weight reduction involves a mechanism that is independent of the amount of food consumed by the animals. The drop in body weight may be due to several mechanisms like enhanced thermogenesis, reduced lipid digestion-transport, reduced lipogenesis-adipogenesis and increased lipolysis or energy expenditure [2].
In the body, adipose tissue is a key site of energy storage and is imperative for energy homeostasis. Nevertheless, long-term consumption of HFD causes obesity and insulin resistance possibly by reducing the interaction between insulin and insulin receptor substrate-1 (IRS-1) via diacylglycerol signaling [38, 41]. In the present study, rats fed with HFD have developed insulin resistance as indicated by amplified plasma insulin and glucose (Table 3), which is possibly due to impairment in the regulation of insulin-mediated glucose uptake in skeletal muscles or possibly through regulation of cell energy metabolism or reducing free fatty acids. Our results with piperonal demonstrating its insulin sensintizing activity are in line with the studies of Uma et al. [38] and Li et al. [25].
Leptin and adiponectin are the two most studied adipocyte-secreted hormones which have a major influence on energy balance and their measurement in plasma level may designate the compassion of an animal-to-weight gain when exposed to an HFD [15, 42]. Leptin secretion is directly proportional to adipose tissue mass as well as nutritional grade [21], whereas adiponectin is inversely correlated with body mass [17]. In the present study, feeding on HFD increased body weight and fat mass, despite an effective decrease in the circulating level of adiponectin and increase of the anorexigenic hormone leptin, a finding reliable with previous reports [43]. Interestingly, piperonal treatment decreased leptin and enhanced adiponectin secretions in plasma of HFD-induced obese rats. This may be due to downregulation of leptin and upregulation of adiponectin by piperonal at the molecular level in adipose tissue [44, 45].
One of the key strategies to suppress obesity is to inhibit the digestion and assimilation of the dietary fats and sugars [43]. Amylase and lipase, the key enzymes in carbohydrate and lipid digestion, are utilized as targets in drug design in an effort to treat obesity and associated disorders. In our study, elevated levels of amylase and lipase were recorded in HFD-fed rats, which were subsequently lowered by piperonal supplementation. So, suppression of these digestive enzymes is therefore beneficial in the treatment of obesity [46].
Antihyperlipidemic and antiobesity effects in animals and humans have become an important issue for molecular nutrition and food research. Supplementation of piperonal significantly lowered TC, TGs, FFAs and PLs in both plasma and liver and LDL-C levels in plasma of HFD-induced obese rats. An earlier report [39] has shown that supplementation of piperonal to HFD-fed animals leads to a hypolipidemic state by decreasing cholesterol absorption from the intestine which leads to lowered availability of FFAs to the liver.
Lipid homeostasis is maintained by lipogenesis and lipolysis, which are strongly associated with obesity development, fatty liver, insulin resistance and type-2 diabetes [43]. During these metabolic derangements, alteration of cell biochemistry and function is known to involve dysregulation of key factors responsible for cell signaling, such as membrane receptors, kinases, phosphatases and transcription factors [47]. The present study indicates that HFD-induced obesity in rats occurs concomitantly with major changes in transcription factors like elevated mRNA expression of PPARγ in adipose tissue and its target genes FAS, Fab-4 and activation of the proinflammatory factor TNF-α; the effects of inflammation in adipose tissue are not limited to insulin signaling alone. In addition, inflammatory signaling in the adipocyte can also upregulate the activity of PPARγ, which is responsible for adipogenesis. PPARγ is known to regulate the transcription of FAS and Fab-4. Fatty-acid synthase, a key lipogenic enzyme, catalyzes the biosynthesis of long chain fatty acids from acetyl-CoA precursors and is activated by binding to its promoter region by SREBP1. Fab-4 is an intracellular fatty acid-binding protein that binds long-chain fatty acids with high affinity. UCP-2, a fat-burning protein, acts as the main regulator of thermogenesis. Elevated plasma FFA, an exogenous ligand for PPARγ, can activate PPARγ through direct interaction with the ligand-binding domain during obesity [48]. It is well known that PPARγ is activated by SREBP1c that leads to decreased FFA oxidation, increased FAS activity and increased lipogenesis. In the present study, supplementation of piperonal altered the expression of PPARγ, FAS, Fab-4, SREBP-1c, TNF-α and UCP-2 to near-normal level in a dose-dependent manner. The reversal effects of piperonal on the expressions of FAS, SREBP-1c, Fab-4, and TNF-α indicate its antiobesogenic activity through regulation of master regulator PPARγ. Elevated expression of UCP-2 with piperonal (40 mg/kg b.wt) treatment shows the thermogenic nature of piperonal causing dissipation of energy through heat. Thus, our findings indicate that treatment of piperonal can attenuate HFD-induced alterations by working on multiple targets [39].
Obesity and hyperlipidemia synergistically endorse systemic oxidative stress disparity between tissue-free radicals, reactive oxygen species (ROS) and antioxidants. Hyperglycemia, elevated lipid levels, inadequate antioxidant defenses and hyperleptinemia could be the possible mechanisms that generate oxidative stress during obesity. ROS could react with polyunsaturated fatty acids, which leads to lipid peroxidation, a renowned parameter for assessing oxidative stress. In the present study, elevated plasma TBARS levels in HFD-induced obese rats suggested enhanced lipid peroxidation leading to tissue damage and incapability of antioxidant defense mechanisms to avert free radical attack. Intracellular antioxidant enzymes and TBARS are the specific markers of oxidative damage at the cellular level [26, 47]. An earlier report by us and others depicted that the lowered level of cellular oxidative damage is connected with multiple enzymatic (SOD, CAT, GPx) and non-enzymatic antioxidant (GSH) defense systems present in cells [18, 26, 43]. Unremitting treatment with Piperonal considerably improved the levels of endogenous antioxidant enzymes (SOD, CAT, GPx) and non-antioxidant enzyme (GSH), and prohibited membrane damage by diminishing lipid peroxidation compared to HFD control. This was further supported by histopathological analysis of liver and adipose tissues.
In the present study, histopathological examination of the liver of the HFD rats showed microvesicular steatosis in hepatocytes as well as more amounts of fat droplets. Piperonal treatment at 40 mg/kgb.wt ameliorated these hepatic lesions partially. Similarly, the prominent changes observed in adipocyte sizes and volume of HFD-fed rats are considerably alleviated in piperonal and Orlistat-treated groups.
Conclusions
The present study substantiates that piperonal effectively inhibited adipogenesis possibly by acting on transcription factors like PPARγ and its target genes like FAS, UCP2 and Fab-4, and pro-inflammatory factors in adipose tissues. These modes of action on modulating genes associated with adipogenesis and lipid metabolism by piperonal are considered relatively novel when compared with the mechanisms reported hitherto with other anti-obesity phytochemicals. Finally, we conclude that piperonal attenuates obesity and associated ailments by working on multiple targets and paves the way to develop a novel herbal formulation.
Notes
Acknowledgements
Authors are thankful to Department of Bio Technology-New Delhi, India (Grant No: BT/PR7799/PBD/17/849/2013) for providing Senior Research Fellowship and Financial Assistance to carry out this research work and also thankful to Dr. Rama Rao (Indian Institute of Chemical Technology-India), Dr. Siddaram Gouda (MRI, Research officer) at Amritha Institute of Medical Science, Kochi, Dr. R Ravindar Naik (Technical Officer, NCLAS, NIN), Dr. JJ Babu (Head & Incharge, DXA), Dr. MV Surekha (Pathologist) National Institute of Nutrition-India, for their constant encouragement and their valuable suggestions.
Ethical approval
Animal experiments were performed at National Center for Laboratory Animal Sciences, National Institute of Nutrition, Hyderabad, India (Regd. No. 154/RO/C/1999a/CPCSEA). All procedures involving laboratory animals were in accordance with the Institute Animal Ethical Committee (IAEC No: 36 a/2012(i)/a/−CPCSEA/−IAEC/SVU/MB; dt.01.07.2012).
Funding
Department of Bio Technology, Ministry of Science and Technology, Government of India, New Delhi, India. Award No: BT/PR7799/PBD/17/849/2013. Recipient: Balaji Meriga.
Availability of data and materials
All raw data, materials and histology samples are available with Principal Investigator & Corresponding author Dr. Balaji Meriga.
Authors’ contributions
Conceived and designed the experiments; PBN and MB. Performed experiments; PBN, RRN, HSN, PS, VRC, UVVS, GS. Analyzed data: PBN, PS, RRN and MB. Contributed reagents materials/analysis tools: MB. Wrote the paper: PBN, GS and MB. All authors read and approved the final manuscript.
Consent for publication
All authors approved the final version of this manuscript.
Competing interests
All authors declare that they have no competing interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic disease. Nat Rev Immunol. 2008;8(12):9232–4.CrossRefGoogle Scholar
- 2.Balaji M, Ganjayi MS, Hanuma Kumar GE, Parim BN, Mopuri R, Dasari SA. Review on possible therapeutic targets to contain obesity: the role of phytochemicals. Obes Res Clin Pract. 2016;10(4):363–80.CrossRefPubMedGoogle Scholar
- 3.Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104(4):531–43.CrossRefPubMedGoogle Scholar
- 4.Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor SREBP-1c. Biochem J. 2002;366:377–91.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.OECD obesity Update 2014: ww.oecd.org/health/obesity-update.html.
- 6.Boissonneault GA. Obesity: the current treatment protocols. JAAPA. 2009;22:18–9.PubMedGoogle Scholar
- 7.Gopalan C. The changing nutrition scenario. Indian J Med Res. 2013;138(3):392–7.PubMedPubMedCentralGoogle Scholar
- 8.Jia H, Lubetkin EI. Obesity related quality adjusted life years in lost in the U.S. from 1993 to 2008. Am J Prev Med. 2010;39(3):220–7.CrossRefPubMedGoogle Scholar
- 9.Gonzalez-Castejon M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: a review. Pharmacol Res. 2011;64(5):438–55.CrossRefPubMedGoogle Scholar
- 10.Vermaak I, Viljoen AM, Hamman JH. Natural products in antiobesity therapy. Nat Prod Rep. 2011;28(9):1493–533.CrossRefPubMedGoogle Scholar
- 11.Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, Bapat R, Kwun I, Shen CL. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25(1):1–18.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Brahma Naidu P, Uddandrao VV, Ravindar Naik R, Suresh P, Meriga B, Begum MS, Pandiyan R, Saravanan G. Ameliorative potential of gingerol: Promising modulation of inflammatory factors and lipid marker enzymes expressions in HFD induced obesity in rats. Mol Cell Endocrinol. 2016;419:139–47.CrossRefPubMedGoogle Scholar
- 13.Kliewer SA, HE W, Lambert MH, Willson TM. Peroxisome proliferator activated receptors: from genes to physiology. Recent Prog Horm Res. 2001;56:239–63.CrossRefPubMedGoogle Scholar
- 14.Seo JB, Moon HM, Noh MJ, Lee YS, Jeong HW, Yoo EJ, Kim WS, Park J, Youn BS, Kim JW, Park SD, Kim JB. Adipocyte determination and differentiation dependent factor1/sterol regulatory element binding protein 1c regulates mouse adiponectin expression. J Biol Chem. 2002;279(21):22108–17.CrossRefGoogle Scholar
- 15.Christodoulides C, Vidal-Pulg APPAR. Adipocyte function. Mol Cell Endocrinol. 2010;318(1–2):61–8.CrossRefPubMedGoogle Scholar
- 16.Stienstra R, Duval C, Mullaer M, Kersten SPPAR. Obesity, and inflammation. PPAR Res. 2007:95974.Google Scholar
- 17.Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409–35.CrossRefPubMedGoogle Scholar
- 18.Lenhard JM. Lipogenic enzymes as therapeutic targets for obesity and diabetes. Curr Pharm Des. 2011;17(4):325–31.CrossRefPubMedGoogle Scholar
- 19.Butt MS, Pasha I, Sultan MT, Randhawa MA, Saeed F, Ahmed W. Black pepper and health claims: a comprehensive treatise. Crit Rev Food Sci Nutr. 2013;53(9):875–86.CrossRefPubMedGoogle Scholar
- 20.Samykutty A, Shetty AV, Dakshinamoorthy G, Bartik MM, Johnson GL, Webb B, Zheng G, Chen A, Kalyanasundaram R, Munirathinam G. Piperine, a bioactive component of pepper spice exerts therapeutic effects on androgen dependent and androgen independent prostate cancer cells. PLoS One. 2013;8(6):e65889.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Santiago VS, Alvero RG, Vilasenor IM. Aedes Aegypti larvivide from the ethanolic extract of Piper nigrum black peppercorns. Nat Prod Res. 2015;29(5):441–3.CrossRefPubMedGoogle Scholar
- 22.Chonpathompikunlert P, Wattanathorn J, Muchimapura S. Piperine: the main alkaloid of Thai black pepper, protects against neurodegenration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer’s disease. Food Chem Toxicol. 2010;48(3):798–802.CrossRefPubMedGoogle Scholar
- 23.Srinivasan K, Patole PS, Kaul C, Ramarao P. Reversal of glucose intolerance by pioglitazone in high fat diet fed rats. Exp. Clin Pharmacol. 2004;26(5):327–33.Google Scholar
- 24.Meghwal M, Goswami TK. Piper nigrum and piperine: an update. Phytother Res. 2013;8:1121–30.CrossRefGoogle Scholar
- 25.Li X, Choi Y, Yanakawa Y, Park T. Piperonal prevents high fat diet induced hepatic steatosis and insulin resistance in mice via activation of adiponectin/AMPK pathway. Int J Obes. 2014;38(1):140–7.CrossRefGoogle Scholar
- 26.BrahmaNaidu P, Nemani H, Meriga B, Mehar SK, Pothana S, Ramgopalarao S. Mitigating efficacy of piperine in the physiological derangements of high fat diet induced obesity in Sprague dawley rats. Chem Biol Interact. 2014;221:42–51.CrossRefPubMedGoogle Scholar
- 27.Rao VR, Raju SS, Sarma VU, Sabine F, Babu KH, Babu KS, Rao JM. Simultaneous determination of bioactive compounds in Piper nigrum L. and a species comparision study using HPLC-PDA. Nat Prod Res. 2011;25(13):1288–94.CrossRefPubMedGoogle Scholar
- 28.Morbach CA, Brans YW. Determination of body composition in growing rats by total body electrical conductivity. J Pedia Gastro Nutr. 1992;14:2873–92.CrossRefGoogle Scholar
- 29.Montero M, Diaz-Curiel M, Guede D, Caeiro JR, Martin-Fernandez M, Rubert M, Navarro D, De la Piewdra C. Effect of Kalsis, a dietary supplement, on bone metabolism in the ovariectomized rats. J Osteopros 2012: 639427.Google Scholar
- 30.Floch J, Lees M, Sloane Stanley GHA. Simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226(1):497–509.Google Scholar
- 31.Taylor BA, Phillips SJ. 1996. Detection of obesity QTLs on mouse chromosomes 1 and 7 by selective DNA pooling. Genomics. 1996;34(3):389–98.CrossRefPubMedGoogle Scholar
- 32.Fraga CG, Leibouitz BE, Toppel AL. Lipid peroxidation measured as TBARS in tissue slices: characterization and comparison with homogenates and microsomes. Free Radic Biol Med. 1988;4(3):155–61.CrossRefPubMedGoogle Scholar
- 33.Aebi H. Catalase in vitro. Meth Enzymol. 1984;105:121–6.CrossRefPubMedGoogle Scholar
- 34.Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–7.CrossRefPubMedGoogle Scholar
- 35.Kakkar B, Das P, Viswanathan N. A modified spectrophotometric assay of SOD. Ind J Biochem Biophy. 1984;21:130–2.Google Scholar
- 36.Paglia D, Valentine W. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158.169.Google Scholar
- 37.Esser N, Legrand-Poels S, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diab Res Clin Pract. 2014;105(2):141–50.CrossRefGoogle Scholar
- 38.Uma B, Vinay K, Naresh K. The effect of high fat diet induced obesity on cardiovascular toxicity in wistar albino rats. Hum Exp Toxicol. 2011;30(9):1313–21.CrossRefGoogle Scholar
- 39.Kyung JK, Myoung-Su L, Keunae J. Piperonal alkaloids from Piper Retrofractum Piper Retrofractum Vahl. Protect against high fat diet induced obesity by regulating lipid metabolism and activating AMP-activated protein kinase. Bioche Biophys Res Commun. 2011;411:219–25.CrossRefGoogle Scholar
- 40.Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE. Weight as a risk factor for clinical diabetes in women. Am J Epidemilo. 1990;132(3):510–3.Google Scholar
- 41.Despina H, Antoine Diane V. Populus balsamifera L. (Salicaceae) mitigates the development of obesity and improves insulin sensitivity in a diet-induced obese mouse model. J Ethnopharmacol. 2012;141(3):1012–20.CrossRefGoogle Scholar
- 42.Floh B, Floh R. Basic principles and emerging concepts in the redox control of transcription factors. Antioxid Redox Signal. 2011;15:2335–81.CrossRefGoogle Scholar
- 43.Parim B, Harishankar N, Balaji M, Pothana S, Sajjalaguddam RR. Effects of Piper Nigrum extracts: restorative perspectives of high fat diet induced changes on lipid profile, body composition, and hormones in Sprague-dawley rats. Pharmaceutical Biol. 2015;53(9):1318–28.CrossRefGoogle Scholar
- 44.Srinivasan K. Black pepper and its pungent principle piperine: a review of diverse physiological effects. Crit Rev Food Sci. 2007;47(8):735–48.CrossRefGoogle Scholar
- 45.Sung YY, Yoon T, Kyang W. Anti-obesity effects of Geranium Thunbergii extract via improvement of lipid metabolism in high-fat diet-induced obese mice. Mol Med Rep. 2011;4:1107–13.PubMedGoogle Scholar
- 46.Staiger H, Haring HU. Adipocytokines: fat-derived humoral mediators of metabolic homeostasis. Exp Clin Endocrinol Diabetes. 2005;113(2):67–79.CrossRefPubMedGoogle Scholar
- 47.Saravanan G, Ponmurugan P, Deepa MA, Senthilkumar B. Anti-obesity action of gingerol: effect on lipid profile, insulin, leptin, amylase and lipase in male obese rats induced by a high-fat diet. J Sci food Agri. 2014;94(14):2972–7.CrossRefGoogle Scholar
- 48.Magana MM, Osborne TF. Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter. J Biol Chem. 1996;271:32689–94.CrossRefPubMedGoogle Scholar
Copyright information
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.